Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

NASDAQ:OCGN

Ocugen, Inc.

Last Close

1.98

17/05 20:00

Market Cap

491.50M

Beta: 3.71

Volume Today

6.43M

Avg: 6.32M

PE Ratio

−1.82

PFCF: −1.70

People Not Available